Nasus Pharma Ltd income statement NSRX
In fiscal 2025, which ended Dec 31, 2025, Nasus Pharma Ltd reported revenue of $1.2 billion. It recorded a net loss of $5.9 million. The operating loss came to $4.9 million, an operating margin of -0.4%. Diluted earnings per share were -$0.72.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Dec 31, 2025
|
|---|---|
| Revenue |
1,235
|
| Research and development |
2
|
| Selling, general and administrative |
3
|
| Operating income |
-5
|
| Net income |
-6
|
| Net income to common |
6
|
| Basic EPS |
-0.72
|
| Diluted EPS |
-0.72
|
| Weighted average shares, basic |
8
|
| Weighted average shares, diluted |
8
|
| Margins | |
| Operating margin |
-0.40%
|
| Profit margin |
-0.47%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NSRX (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Tel Aviv - Yafo, Israel
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2029039
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.